No Data
No Data
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Piper Sandler Sticks to Their Buy Rating for IO Biotech (IOBT)
IO Biotech | 10-K: FY2024 Annual Report
IO Biotech Announces Acceptance Of Abstracts To Be Presented At 2025 American Association for Cancer Research Annual Meeting
Express News | IO Biotech Announces Acceptance of Abstracts to Be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
12 Health Care Stocks Moving In Tuesday's Intraday Session